Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The rationale: Concerns about safety and the fact that Wegovy is specifically formulated and studied for obesity at the 2.4mg dose, while Ozempic is approved for diabetes at lower doses
B.ElbrondB.RolanP.ZdravkovicM
They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose
Firm pressure for 30-60 seconds
These medications work by curbing appetite and slowing digestion, naturally leading to lower calorie intake
If needed, we can also prepare a higher concentration of 3mg/ml which will carry an increased price
,aspect=ignore)
